154 publications
Name | Date | Type | Actions |
---|---|---|---|
2009 annual earnings March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements. |
Public releases | ||
CONVOCATION : assemblée d'actionnaires et de porteurs de parts Avis de réunion valant avis de convocation. <br> |
Shareholders´s Meeting | ||
Assemblée Générale Ordinaire du 7 mai 2010 : texte des résolutions PREMIERE RESOLUTION : Approbation des comptes sociaux de l’exercice 2009 |
Shareholders´s Meeting | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - February2010 As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers » |
Voting rights | ||
Programme de rachat - février 2010(french) Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres |
Monthly communication regarding buyback programs | ||
Redemption of tranche A bonds February 26, 2010 (Lure, France) - Following the decision of Soparfin (family holding Etienne Frechin) not to convert the tranche A convertible bonds when they reach maturity on February 27, 2010, Vétoquinol has redeemed the bonds. |
Public releases | ||
Déclaration dirigeants SOPARFIN Déclaration individuelle relative aux opérations des personnes |
Monthly communication regarding buyback programs | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - January 2010 As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers » |
Voting rights | ||
Programme de rachat - janvier 2010(french) Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres |
Monthly communication regarding buyback programs | ||
Strong growth in 2009 Revenues: +7.6% January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions. |
Public releases |